Because PGE2 synthetized via COX-2 suppresses neuronal excitability31 and the COX-2 - EP4 signaling pathway has been implicated in the progression of ischemic injury32, 33, we assessed the impact of the chosen pharmacological treatments on the DC signature of SD, as well. The gene discussed is PTGS2; the disease is Salla disease.